300937.SHE Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
- Market cap
- CNY 2.03B
- P/E
- -
- P/B
- 2.50x
- ROE
- -2.6%
- Dividend yield
- 0.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 300937.SHE undervalued?
Graham numberThe Graham number of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. fundamental analysis
No fundamental analysis for Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. yet.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It offers pharmaceutical products, such as Western medicine, traditional Chinese medicine preparations, Chinese herbal medicine pieces and raw materials, food and health food, medical devices; and non-pharmaceutical products and others. The company also provides clinics, E-commerce platform operation, logistics and distribution, management consult…
Full company profileSichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.29B | 2.79B | 3.40B | 3.97B | 4.43B | 4.39B | 4.45B | 4.36B |
| Gross Profit | 209M | 198M | 186M | 315M | 368M | 393M | 463M | 400M |
| Operating Income | 82.4M | 70.1M | 10.5M | 79.8M | 96.5M | 43.5M | 44.8M | 15.3M |
| EBITDA | 89.7M | 73.7M | 26.5M | 75.6M | 104M | 92.3M | 65.8M | -13.3M |
| Net Income | 64.7M | 54.0M | 6.40M | 40.7M | 54.8M | 14.9M | -11.2M | -21.1M |
| EPS | 0.90 | 0.75 | 0.07 | 0.43 | 0.57 | 0.16 | -0.12 | -0.22 |
| Balance Sheet | ||||||||
| Total Assets | 744M | 845M | 1.19B | 1.59B | 1.68B | 1.70B | 1.73B | 1.93B |
| Total Liabilities | 257M | 319M | 399M | 772M | 831M | 867M | 925M | 1.15B |
| Shareholders' Equity | 476M | 518M | 774M | 811M | 847M | 841M | 820M | 810M |
| Cash & Short-term Investments | 123M | 114M | 154M | 458M | 375M | 387M | 409M | 385M |
| Cash Flow | ||||||||
| Operating Cash Flow | 42.3M | 69.3M | -154M | 153M | -115M | 124M | -13.2M | - |
| Capital Expenditure | 36.4M | 35.2M | 31.4M | 18.3M | 35.3M | 32.4M | 7.57M | 13.9M |
| Free Cash Flow | 5.89M | 34.1M | -186M | 134M | -151M | 92.0M | -20.8M | 393K |
| Ratios | ||||||||
| ROE | 13.6% | 10.4% | 0.8% | 5.0% | 6.5% | 1.8% | -1.4% | -2.6% |
| ROA | 8.7% | 6.4% | 0.5% | 2.6% | 3.3% | 0.9% | -0.6% | -1.1% |
| Net Profit Margin | 2.8% | 1.9% | 0.2% | 1.0% | 1.2% | 0.3% | -0.3% | -0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. dividends
- Dividend yield
- 0.88%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 13, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.8M | 0.19 | - |
| 2024 | CNY 30.3M | 0.32 | 203.5% |
| 2023 | CNY 24.1M | 0.25 | 44.0% |
| 2022 | CNY 5.31M | 0.06 | 13.0% |
| 2021 | CNY 20.7M | 0.22 | 322.9% |
| 2020 | CNY 12.6M | 0.18 | 23.4% |
| 2019 | CNY 1.94M | 0.03 | 3.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
- Insiders 54.45%
- Institutions 0.63%
- Public & others 44.93%
- Shares outstanding 95.7M
- Free float 43.2M
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. company profile
- Company name
- Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
- Ticker
- 300937.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Consumer Staples Distribution & Retail
- Employees
- 1,045
- Fiscal year end
- December
- Address
- No. 18, Youlian 1st Street, Chengdu, China, 610081
- Phone
- 86 28 6956 9969
- Website
- hezongyy.com
About Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It offers pharmaceutical products, such as Western medicine, traditional Chinese medicine preparations, Chinese herbal medicine pieces and raw materials, food and health food, medical devices; and non-pharmaceutical products and others. The company also provides clinics, E-commerce platform operation, logistics and distribution, management consulting, warehousing, cultural and artistic exchange, drug sale and retail chain, technology promotion and application, internet hospital, other organizational management, new media operation, equipment sales, and software development services, and information technology services, as well as engages in medical research and experimental development, and online pharmaceutical retail businesses. The company was founded in 2007 and is based in Chengdu, China.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. management
4- Mr. Shunjun ChenChairman & GM · born 1977
- Mr. De Qiang ZhengDeputy GM & Financial Director · born 1984
- Ms. Mingyi WangDeputy GM & Board Secretary · born 1984
- Fei WenAccounting Supervisor